Scientists believe they’ve developed vaccine to stop deadly effect of fentanyl
Vaccine contains adjuvant derived from E coli which boosts immune system’s response to it
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Scientists have reportedly developed a vaccine that could potentially block the ability of synthetic opioid fentanyl from entering the brain and eliminate its deadly effects.
The findings by the researchers at the University of Houston which were published in the journal Pharmaceutics have been called a "game changer" at a time when America is reeling under one of its worst opioid crises.
According to the Centers for Disease Control and Prevention, more than 71,000 people died of a fentanyl overdose last year, while the total number of deaths due to drug abuse stood over 100,000.
The synthetic opioid is nearly 50 times stronger than heroin and a dose of only two milligrams could be fatal depending on the person's size. It is smuggled into the US by Mexican drug cartels and sold by lacing it with street drugs such as cocaine, methamphetamine, and Xanax.
Colin Haile, a research associate professor and the study's lead author, said the vaccine is able to generate anti-fentanyl antibodies that bind to the consumed opioid and prevent it from entering the brain and pushing it out of the body via the kidneys.
The vaccine thus prevents a person from feeling the "euphoric effects" or the fentanyl high.
It contains an adjuvant derived from E coli called dmLT which boosts the immune system's response to vaccines, increasing their effectiveness.
Mr Haile said that the antibodies were specific to fentanyl and the derivative did not cross-react with other opioids such as morphine, which allows a person vaccinated for fentanyl to seek treatment for other opioids.
The “preclinical results demonstrate efficacy in neutralizing fentanyl’s effects and warrant further development as a potential therapeutic for opioid use disorder and overdose in humans”, the study said.
The clinical studies on the vaccine did not cause adverse side effects in the immunised rats involved, it said.
The team will manufacture clinical-grade vaccines with clinical trials in humans in the coming months and expects “minimal side effects” as two of the components in the vaccine are already in “other vaccines on the market”.
Meanwhile, The FDA is investigating reports that animal tranquilizers — colloquially called “tranq” — are being mixed with heroin and fentanyl with potentially fatal results.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments